Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 2
Submit an article Journal homepage
310
Views
38
CrossRef citations to date
0
Altmetric
Review

New advances in antibiotic development and discovery

Michael N Alekshun Paratek Pharmaceuticals, Inc., 75 Kneeland Street, Boston, MA 02111 Boston, MA 02111, USA. [email protected]
Pages 117-134 | Published online: 22 Apr 2005

Bibliography

  • INFECTIOUS DISEASES SOCIETY OF AMERICA: Special report: bad bugs, no drugs: as antibiotic discovery stagnates.. .a public health crisis brews. (2004).
  • ••A current report on the state of affairs ofantibiotic resistance and antibiotic therapies.
  • SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279–1286.
  • ••A synopsis of current pharmaceutical drugpipelines.
  • WENZEL RP: The antibiotic pipeline-challenges, costs, and values. N Engl. J. Med. (2004) 351(6):523–526.
  • SHLAES DM: The abandonment of antibacterials: why and wherefore? Curr. Opin. Pharmacol (2003) 3(5):470–473.
  • HIRAMATSU K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. (2001) 1(3):147–155.
  • NAIMI TS, LEDELL KH,-SABETTI K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. IA/VIA (2003) 290(22):2976–2984.
  • KARLOWSKY JA, THORNSBERRY C, JONES ME, SAHM DF: Susceptibility of antimicrobial-resistant urinary Escherichia cob isolates to fluoroquinolones and nitrofurantoin. Clin. Infect. Dis. (2003) 36(2):183–187.
  • LEVIN AS, BARONE AA, PENCO Jet al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin. Infect. Dis. (1999) 28(5):1008–1011.
  • •This report describes the last therapeutic option for MDR Gram-negative infections refractory to all other therapies.
  • ELIOPOULOS GM: Current and new antimicrobial agents. Am. Heart J. (2004) 147(4):587–592.
  • MEKA VG, GOLD HS: Antimicrobial resistance to linezolid. Clin. Infect. Dis. (2004) 39(7):1010–1015.
  • MANDELL LA, BARTLETT JG, DOWELL SF et al: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37(11):1405–1433.
  • ZHANEL GG, HOMENUIK K, NICHOL K et al: The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 64(1):63–88.
  • ZHANG YY, ZHOU L, ZHU DM et al: In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn. Microbial. Infect. Dis. (2004) 50(4):267–281.
  • BAUER G, BERENS C, PROJAN SJ, HILLEN W: Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2' cleavage of 16S rRNA. Antimicrob. Chemother. (2004) 53(4):592–599.
  • FRITSCHE TR, JONES RN: Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob Agents (2004) 24(6):567–571.
  • HERRERO IA, ISSA NC, PATEL R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl. J. Med. (2002) 346(11):867–869.
  • MURALIDHARAN G, MICALIZZI M, SPETH J, RAIBLE D, TROY S: Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):220–229.
  • POSTIER RG, GREEN SL, KLEIN SR, ELLIS-GROSSE EJ, LOH E: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin- infections in hospitalized patients. Clin. Ther. (2004) 26(5):704–714.
  • DARTOIS N, TIGECYCLINE 305 cSSSI STUDY GROUP: Results of a Phase III, double-blind, safety and efficacy study comparing tigecycline with vancomyciniaztreonam to treat complicated skin and skin-structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • MACONE A, DONATELLI J, T, LEVY SB, TANAKA SK: In vitro activity of PTK 0796 against Gram-positive and Gram-negative organisms. 43rd Interscience Conference on Antimicrobial Agents and Chemotheapy. Chicago, IL, USA (2003).
  • BROETZ-OESTERHELT H, ENDERMANN R, LADEL CH, LABISCHINSKI H: Superior efficacy of BAY 73–7388, a novel aminomethylcycline, compared with linezolid and vancomycin in murine sepsis caused by susceptible or multiresistant staphylococci. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004).
  • McKENNEY D, QUINN JM, CL et al: Evaluation of PTK 0796 in experimental models of infections caused by Gram-positive and Gram-negative pathogens. 43rd Interscience Conference on Antimicrobial Agents and Chemotheapy. Chicago, IL, USA (2003).
  • McKENNEY D, QUINN JM, CL et al: The efficacy of PTK 0796 in murine models of Streptococcus pneumoniae. 43rd Interscience Conference on Antimicrobial Agents and Chemotheapy. Chicago, IL, USA (2003).
  • ENDERMANN R, LADEL CH, BROETZ-OESTERHELT H, LABISCHINSKI H: BAY 73–7388 is highly efficacious in animal models of intra-abdominal infections caused by a range of aerobic and anaerobic organisms, including VRE. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004).
  • PAGE MG: Cephalosporins in clinical development. Expert Opia Investig. Drugs (2004) 13(8):973–985.
  • HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P et al: In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2001) 45(3):825–836.
  • SCHMITT-HOFFMANN A, NYMAN L, ROOS B et al.: Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(7):2576–2580.
  • SCHMITT-HOFFMANN A, ROOS B, SCHLEIMER M et al: Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(7):2570–2575.
  • HEEP M, QUERNER S, HARSCH M, O'RIORDAN W: Ceftobiprole (BAL-5788), the first of a new class of anti-MRSA cephalosporins-microbiological results from a Phase II study in complicated skin and skin-structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy Washington, DC, USA (2004).
  • TSUJI M, ISHII Y, OHNO A, S, YAMAGUCHI K: LI vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. (1998) 42(1):94–99.
  • JONES RN, HUYNH HK, BIEDENBACH DJ: Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. (2004) 48(8):3136–3140.
  • GE Y, WIKLER MA, SAHM DF, BLOSSER-MIDDLETON RS, KARLOWSKY JA: In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. (2004) 48(4):1384–1396.
  • MASUDA N, SAKAGAWA E, OHYA S et al.: Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aerugMosa. Antimicrob. Agents Chemother. (2000) 44(12):3322–3327.
  • MUSHTAQ S, GE Y, LIVERMORE DM: Doripenem versus Pseudomonas aerugMosa in vitro: activity against characterized isolates, mutants, and transconjugants and selection potential. Antimicrob. Agents Chemother. (2004) 48(8):3086–3092.
  • FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. 44th Mterscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC (2004).
  • FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC (2004).
  • NAKAJIMA Y, MIZOBUCHI M, NAKAMURA M et al.: Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab. Dispos. (2004) 32(12):1383–1391.
  • BUSH K, MACIELAG M,-WELLS M: Taking inventory: antibacterial agents currently at or beyond Phase I. Curr. Opin. Microbial. (2004) 7(5):466–476.
  • •This timely review focuses on current antibiotics in early- to late-stage clinical development programmes.
  • THOMSON KS, MOLAND ES: CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. I Antimicrob. Chemother. (2004) 54(2):557–562.
  • JACOBS MR, BAJAKSOUZIAN S, WINDAU A et al.: In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother. (2004) 48(9):3338–3342.
  • PERIC M, JACOBS MR, PC: Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared with those of nine other agents. Antimicrob. Agents Chemother. (2004) 48(8):3188–3192.
  • MAHARAJ N, JHA R, CHUGH Y et al: A phase-I study of escalating single doses of intravenous (IV) WCK 771. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • MILATOVIC D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob. Agents Chemother. (2000) 44(4):1102–1107.
  • DALHOFF A, SCHMITZ FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. Microbio. Infect. Dis. (2003) 22(0203–221.
  • DAWE RS, IBBOTSON SH, SANDERSON JB, THOMSON EM, FERGUSON J: A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. BE .1 Dermatol (2003) 149(6):1232–1241.
  • SHETTY N, WILSON AP: Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. I Antimicrob. Chemother. (2000) 46(4):633–638.
  • GAJJAR DA, BELLO A, GE Z, CHRISTOPHER L, GRASELA DM: Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. (2003) 47(7):2256–2263.
  • VAN WART S, PHILLIPS L, EA et al.: Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. (2004) 48(12):4766–4777.
  • PANKUCH GA, KELLY LM, LIN Get a/.: Activities of a new oral streptogramin, XRP 2868, compared with those of other agents against Streptococcus pneumoniae and Haemophilus species. Antimicrob. Agents Chemother. (2003) 47(10):3270–3274.
  • KOSOWSKA K, CREDITO K, PANKUCH GA et al: Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus inIkenzae. Antimicrob. Agents Chemother. (2004) 48(10:4113–4119.
  • MATIC V, KOSOWSKA K, B et al: Anti-pneumococcal activities of two novel macrolides, 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob. Agents Chemother. (2004) 48(10:4103–4112.
  • SCORNEAUX B, ARYA A, A et al: In vitro and in vivo evaluation of EP-13420: a novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. 43rd Llterscience Conference on Antimicrobial Agents and Chemotheapy. Chicago, IL, USA (2003).
  • XIONG L, KORKHIN Y, MANKIN AS: Binding site of the bridged macrolides in the Escherichia coil ribosome. Antimicrob. Agents Chemother. (2005) 49(1):281–288.
  • EGGERT US, RUIZ N, FALCONE BV et al.: Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin. Science (2001) 294(5541):361–364.
  • ALEKSHUN MN: 44th Interscience Conference on Antimicrobial Agents and Chemotheapy: an update on new antibiotics, novel non-antibacterial treatment modalities and critical issues in antibiotic resistance. Expert Opin. Investig. Drugs (2005) 14(1):93–99.
  • VAN BAMBEKE F: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curt: Opin. Pharmacol (2004) 4(5):471–478.
  • DOWELL JA, SELTZER E, M, MARBURY T: The pharmacokinetics of dalbavancin (DAL) in subjects wilt mild, moderate or severe hepatic impairment (HI). 44th Llterscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • BHAVNANI SM, PASSARELL JA, OWEN JS et al.: Pharmacokinetic-pharmacodynamic (PK/PD) analysis and efficacy of oritavancin in patients with Staphylococcus aureus (SA) bacteremia. 44th Llterscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • SHAW JP, SEROOGY J, KANIGA K et al: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):195–201.
  • BARRIERE S, GENTER F, SPENCER E et al.: Effects of a new antibacterial, telavancin, on cardiac repolarisation (QTc interval duration) in healthy subjects.. Pharmacol (2004) 44(7):689–695.
  • MONTECALVO MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant infection in high-risk patients. Antimicrob. Chemother. (2003)m 51 (Suppl. 3) : iii31-iii35.
  • SCHNEIDER P, HAWSER S, ISLAM K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. (2003) 13(23):4217–4221.
  • KOHLHOFF SA, ROBLIN PM, REZNIK T et al: Li vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and. pneumoniae. Antimicrob. Agents. (2004) 48(5):1885–1886.
  • DARST SA: New inhibitors targeting bacterial RNA polymerase. Trends Biochem. ScL (2004) 29(4):159–160.
  • ROTHSTEIN DM, HARTMAN AD, CYNAMON MH, EISENSTEIN BI: Development potential of rifalazil. Expert Opin. Investig. Drugs (2003) 12(2):255–271.
  • DIETZE R, TEIXEIRA L, ROCHA LM et al.: Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. (2001) 45(7):1972–1976.
  • BATTEIGER B, McCORMACK W, STAMM W: A double-blind, randomomised trial of rifalazil (Rif) for the treament of nongonococcal urethritis (NGU) and chlamydial infection. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy Washington DC, USA (2004).
  • BLASI F, TARSIA P, COSENTINI R, VALENTI V: Newer antibiotics for the treatment of respiratory tract infections. Curt: Opin. Pulm. Med. (2004) 10(3):189–196.
  • EDNIE LM, RATTAN A, JACOBS MR, APPELBAUM PC: Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents Chemother. (2003) 47(3):1143–1147.
  • HOELLMAN DB, LIN G, EDNIE LM et al.: Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. (2003) 47(3):1148–1150.
  • MATHUR T, BHATEJA P, PANDYA M, FATMA T, RATTAN A: In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria. Int. J. Antimicrob. Agents (2004) 24(4):369–373.
  • FLUIT AC, SCHMITZ FJ, VERHOEF J, MILATOVIC D: In vitro activity of AZD-2563, a novel oxazolidinone, against European Gram-positive cocci.. Chemother. (2002) 50(2):271–276.
  • WOOKEY A, TURNER PJ, JM et al: AZD-2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Gbh Microbiol Infect. (2004) 10(3):247–254.
  • YONG D, YUM JH, LEE K et al: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. (2004) 48(1):352–357.
  • ACKERMANN G, LOFFLER B, ADLER D, RODLOFF AC: LI vitro activity of OPT-80 against Clostridium Antimicrob. Agents Chemother. (2004) 48(6):2280–2282.
  • CREDITO KL, APPELBAUM PC: Activity of OPT-80, a novel macrocycle, compared to those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. (2004) 48(11):4430–4434.
  • SHANGLE S, LEE C, OKUMU F et al: Safety and pharmacokinetics of OPT-80 in human volunteers. 44th Llterscience Conference on Antimicrobial Agents and Chemotheapy Washington, DC, USA (2004).
  • WALLER AS, CLEMENTS JM: Novel approaches to antimicrobial therapy: peptide deformylase. Curt: Opin. Drug Discov. Devel (2002) 5(5):785–792.
  • EDNIE LM, PANKUCH G, APPELBAUM PC: Antipneumococcal activity of LBM-415, a new peptide deformylase inhibitor, compared to those of other agents. Antimicrob. Agents Chemother. (2004) 48(10):4027–4032.
  • CREDITO K, LIN G, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of LBM-415, a new peptide deformylase inhibitor, compared to those of other agents. Antimicrob. Agents Chemother. (2004) 48(10):4033–4036.
  • CHEN D, HACKBARTH C, NI ZJ et al: Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. (2004) 48(1):250–261.
  • APFEL CM, LOCHER H, EVERS S et al: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45(4):1058–1064.
  • MARGOLIS PS, HACKBARTH CJ, YOUNG DC et al: Peptide deformylase in Staphylococcus moms: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44(7):1825–1831.
  • WISE R, ANDREWS JM, ASHBY J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46(4):1117–1118.
  • LOFLAND D, DIFUNTORUM S, WALLER A et al.: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. (2004) 53(4):664–668.
  • RAMANATHAN-GIRISH S, McCOLM J, CLEMENTS JM et al: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 48(12):4835–4842.
  • COKER RJ: Review: multidrug-resistant tuberculosis: public health challenges. Trop. Med. Int. Health (2004) 9(1):25–40
  • ANDRIES K, VERHASSELT P, J et al: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science (2005) 307(5707):223–227.
  • BEGLEY TP, KINSLAND C, STRAUSS E: The biosynthesis of coenzyme A in bacteria. Vitam. Horm. (2001) 61:157–171.
  • GERDES SY, SCHOLLE MD,'SOUZA M et al: From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. (2002) 184(16):4555–4572.
  • CHOUDHRY AE, MANDICHAK TL, BROSKEY JP et al.: Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob. Agents Chemother. (2003) 47(6):2051–2055.
  • BEYER D, KROLL HP, ENDERMANN R et al.: New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob. Agents Chemother. (2004) 48(2):525–532.
  • GUILES JW, TARASOW T, QIU J et al: Novel thiophene-containing inhibitors of bacterial methionyl tRNA synthetase: improved activity resulting from fluorovinylthiophene replacement of arylbromides. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy., DC, USA (2004).
  • CRITCHLEY IA, STONE K, YOUNG C et al: REP8839: a novel methionyl tRNA synthetase inhibitor with potent activity against Staphylococcus aureus and Streptococcus pyogenes. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • HEATH RJ, ROCK CO: Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs (2004) 5(2):146–153.
  • McMURRY LM, OETHINGER M, LEVY SB: Triclosan targets lipid synthesis. Nature (1998) 394:531–532.
  • •Describes the characterisation of the molecular basis of triclosan activity; an antibacterial chemistry widely distributed In consumer products.
  • HEATH RJ, ROCK CO: A triclosan-resistant bacterial enzyme. Nature (2000) 406(6792):145–146.
  • FREIBERG C, BRUNNER NA, SCHIFFER G et al: Identification and characterisation of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. Biol. Chem. (2004) 279(25):26066–26073.
  • LIVERMORE DM: Linezolid in vitro: mechanism and antibacterial spectrum. Antimicrob. Chemother. (2003) 51 (Suppl. 2): ii9-ii16.
  • POOLE K: Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob. Agents Chemother. (2000) 44(9):2233–2241.
  • GORDEEV ME HACKBARTH C, BARBACHYN MR et al: Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett (2003) 13(23):4213–4216.
  • LI Q, LEE JY, CASTILLO R et al: NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against 13-lactamase-producing strains. Antimicrob. Agents Chemother. (2002) 46(5):1262–1268.
  • STONE GW, ZHANG Q, CASTILLO R et al: Mechanism of action of NB2001 and2030, novel antibacterial agents by 13-lactamases. Antimicrob. Agents Chemother. (2004) 48(2):477–483.
  • TEDDER ME, NIE Z, MARGOSIAK S et al.: Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/IVITA nucleosidase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(12):3165–3168.
  • LI X, CHU S, FEHER VA et al: Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors. J. Med. Chem. (2003) 46(26):5663–5673.
  • •Compounds that have the potential to be used as antibacterial and antivirulence agents are described herein.
  • LOWE J, VAN DEN ENT F, AMOS LA: Molecules of the bacterial cytoskeleton. Ann. Rev Biophys. Biomol Struct. (2004) 33:177–198.
  • WANG J, GALGOCI A, KODALI S et al: Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. Biol. Chem. (2003) 278(45):44424–44428.
  • MARGALIT DN, ROMBERG L, METS RB et al: Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Li. USA (2004) 101(32):11821–11826.. WHITE EL, SULING WJ, ROSS LJ, SEITZ LE, REYNOLDS RC: 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. I Antimicrob. Chemother. (2002) 50(1):111–114.
  • DANDLIKER PJ, PRATT SD, AM et al.: Novel antibacterial class.. Agents Chemother. (2003) 47(12):3831–3839.
  • CLARK RF, WANG S, MA Z et al: Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants. Bioorg. Med. Chem. Lett (2004) 14(12):3299–3302.
  • JAYASEKERA MM, ONHEIBER K, KEITH J et al.: Identification of novel inhibitors of bacterial translation elongation factors. Antimicrob. Agents Chemother. (2005) 49(1):131–136.
  • DRLICA K, ZHAO X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol. Rev (1997) 61(3):377–392.
  • NAKADA N, SHIMADA H, HIRATA T et al.: Biological characterisation of cyclothialidine, a new DNA gyrase inhibitor. Antimicrob. Agents Chemother. (1993) 37(12):2656–2661.
  • ANGEHRN P, BUCHMANN S, FUNK C et al.: New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J. Med. Chem. (2004) 47(6):1487–1513.
  • YAGER KM, ALMASSY B, BENSEN D et al.: Structure-based discovery and optimisation of novel antibacterials directed against DNA topoisomerases. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • GRILLOT A, STAMOS D, T et al: A new class of dual targeting inhibitors of GyrB and ParE. 44th Interscience Conference on Antimicrobial Agents and Chemotheapy. Washington, DC, USA (2004).
  • ARTSIMOVITCH I, CHU C, AS, LANDICK R: A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science (2003) 302(5645):650–654.
  • LEPING L, CHEN X, CUTLER ST: Pyrazole antimicrobial agents US patent application 2002/0049205 (2002).
  • LEPING L, CHEN X, FAN P, JT, CULTER S: Antimicrobial agents US patent application 2002/0045749 (2002).
  • BENTLEY R: The shikimate pathway - a metabolic tree with many branches. Grit. Rev Biochem. Mol Biol. (1990) 25(5):307–384.
  • BULLOCH EM, JONES MA, PARKER EJ et al.: Identification of 4-amino-4-deoxychorismate synthase as the molecular target for the antimicrobial action of (6s)-6-fluoroshikimate. J. Am. Chem. Soc. (2004) 126(32):9912–9913.
  • KUNTZ L, TRITSCH D,-BILLIARD C et al: Isoprenoid biosynthesis as target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J. (2004) (In Press).
  • BERTINO J, GREEN L, LIN Y et al: DNA polymerase III holoenzyme (Pol III HE) as a platform for the discovery of new anti-infective agents. 44th Interscience Conference on Antimicrobial Agents and. Washington, DC, USA (2004).
  • TIMSON DJ, SINGLETON MR, WIGLEY DB: DNA ligases in the repair and replication of DNA. Mutat Res. (2000) 460(3-4):301–318.
  • KACZMAREK FS, ZANIEWSKI RP, GOOTZ TD et al: Cloning and functional characterisation of an NAD'-dependent DNA ligase from Staphylococcus aureus. (2001) 183(10):3016–3024.
  • CIARROCCHI G, MacPHEE DG, DEADY LW, TILLEY L: Specific inhibition of the eubacterial DNA ligase by arylamino compounds. Antimicrob. Agents Chemother. (1999) 43(10:2766–2772.
  • BROTZ-OESTERHELT H, I, BARTEL S et al: Specific and potent inhibition of NAD'-dependent DNA ligase by pyridochromanones. I Biol. Chem. (2003) 278(40:39435–39442.
  • GOOD L, AWASTHI SK, DRYSELIUS R, LARSSON O, NIELSEN PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol (2001) 19(4):360–364.
  • KAISERMAN JA, GROSS MI, GE Y et al: DNA binding ligands targeting drug-resistant bacteria: structure, activity, and pharmacology. I Med. Chem. (2003) 46(18):3914–3929.
  • BURLI RW, KAiseRMAN JA, DUAN JX et al.: DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimisation of internal aromatic amino acids. Bioorg. Med. Chem. Lett (2004) 14(9):2067–2072.
  • HU W, BURLI RW, KAIZERMAN JA et al.: DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J. Med. Chem. (2004) 47(18):4352–4355.
  • ALEKSHUN MN, LEVY SB: Targeting virulence to prevent infection: to kill or not to kill? Drug Discov. Today (2004) 1(4):483–489.
  • •A current review of novel non-antibacterial therapies aimed at preventing infection.
  • LOMOVSKAYA O, LEE A, HOSHINO K et al.: Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1999) 43(6):1340–1346.
  • OETHINGER M, KERN WV, JELLEN-RITTER AS, McMURRY LM, LEVY SB: Ineffectiveness of topoisomerase in mediating clinically significant fluoroquinolone resistance in Escherichia coil in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. (2000) 44:10–13.
  • PERIC M, BOZDOGAN B, C et al.: Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus inIkenzae HMC-S. I Antimicrob. Chemother. (2004) 54(2):393–400.
  • DEAN CR, VISALLI MA, PROJAN SJ, SUM PE, BRADFORD PA: Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PA01. Antimicrob. Agents Chemother. (2003) 47(3):972–978.
  • VISALLI MA, MURPHY E, PROJAN SJ, BRADFORD PA: AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. (2003) 47(2):665–669.
  • LOMOVSKAYA O, WARREN MS, LEE A et al: Identification and characterisation of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. (2001) 45(1):105–116.
  • NAKAYAMA K, ISHIDA Y, OHTSUKA M et al: MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds. Bioorg. Med. Chem. Lett. (2003) 13(23):4205–4208.
  • BALL P: Adverse drug reactions: implications for the development of fluoroquinolones. Antimicrob. Chemother. (2003) 51\(Suppl. 1):21–27.
  • RAY WA, MURRAY KT, MEREDITH S et al: Oral erythromycin and the risk of sudden death from cardiac causes. N Engl. J. Med. (2004) 351(11):1089–1096.
  • •This recent report attributes lethal effects to oral erythromycin.
  • TRAN TP, ELLS WORTH EL, STIER MA et al: Synthesis and structural-activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents. Bioorg. Med. Chem. Lett (2004) 14(17):4405–4409.
  • GROSS M, BURLI R, JONES P et al: Pharmacology of novel heteroaromatic polycycle antibacterials. Antimicrob. Agents Chemother. (2003) 47(11):3448–3457.

Websites

  • hdp://www.peninsulapharm.com/press/1027 04pr.html trials of doripenem.
  • http://www.clinicaltrials.govict/gui/show/NC T00091819 trials information comparing telavancin with vancomycin (2004).
  • http://investors.oscient.com/phoenix.zhtml?c =97238&p=irol- &ID=602853 &highlight= Efficacy of ramoplanin versus vancomycin in patients with CDAD.
  • http://217.26.53.107/—arpida/index.php?Me nuID=0 &UserID=1 & ContentID=40 Efficacy of iclaprim versus vancomycin in patients with cSSI.
  • http://www.who.int/mediacentre/factsheets/f s104/en/ World Health Organization fact sheet on Mycobacterium tuberculosis.
  • http://www.fda.gov/OHRMS/DOCKETS/9 8fr/O0n-1463-nfr00001.pdf FDA labeling requirements regarding inappropriate use of systemic antibiotics (2002).
  • http://www.mpexbio.com/pr_0804.html Scheduled clinical trial of an efflux pump inhibitor in patients with cystic fibrosis.
  • http://www.emea.eu.int/pdfs/human/press/p us/233501en.pdf statement on Trovan (2001).
  • http://www.fda.gov/bbs/topics/NEWS/NEW 00279.html statement on temafloxacin (1992).
  • http://www.zyvox.com/indexl.asp Zyvox® label.
  • hdp://www.factive.com/pdf/prescribing_info .pdf® label (2004).
  • http://www.univgraph.com/bayer/inserts/Ave lox.pdf® label (2004).
  • http://www.fda.gov/cder/foillabe1/1999/2106 21bl.pdf® label (1999).
  • http://www.aventis-us.com/PIs/ketek_TXT.html# KetekTm label.
  • http://www.cubist.com/shared/cubicin_label. pdf label.
  • http://www.kingpharm.com/synercid/html/p i.htm® label.
  • http://www.fda.gov/cder/foi/nda/98/21024. htm® approval.
  • http://www.fda.gov/cder/foillabe1/2001/2122 21bl.pdf® label.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.